Welcome to the New Drugwonks.com http://drugwonks.com/index DrugWonks.com | Debating Today's Drugs Policies en-us Thu, 06 Sep 2007 10:55:48 -0400 Sat, 03 Aug 2013 12:20:34 -0400 http://blogs.law.harvard.edu/tech/rss Psyclone WMS 4.4.9 info@drugwonks.com (drugwonks) cpernice@psycloneinc.com (Christopher Pernice) Mooning Healthcare http://drugwonks.com/blog/mooning-healthcare An interesting post at OhMD discusses a new study showing that “96% of patients report leaving their doctor’s office with limited knowledge of how to use the patient portal. Of the 40% of patients who said they had attempted to use the patient portal in 2016, 83% said it was too complicated to use.” That means only 7% of patients find it simple enough to use, and actually care to use it. Mon, 27 Feb 2017 07:18:00 -0500 http://drugwonks.com/blog/mooning-healthcare ProPublica Hides Own Conflicts While Challenging Others http://drugwonks.com/blog/propublica-hides-own-conflicts-while-challenging-others Fri, 24 Feb 2017 14:45:06 -0500 http://drugwonks.com/blog/propublica-hides-own-conflicts-while-challenging-others USA Today: Patient Groups That Get Money Anywhere But Pharma are Conflict Free. http://drugwonks.com/blog/usa-today-patient-groups-that-get-money-anywhere-but-pharma-are-conflict-free Wed, 22 Feb 2017 13:55:12 -0500 http://drugwonks.com/blog/usa-today-patient-groups-that-get-money-anywhere-but-pharma-are-conflict-free A Virtual Ounce of Prevention http://drugwonks.com/blog/a-virtual-ounce-of-prevention The gathering and appraisal of real world evidence can expedite identification of problems before they become deadly. If we can identify misuse earlier, we can help eradicate abuse and addiction.Apps present us with just that opportunity – a virtual ounce of prevention. Tue, 21 Feb 2017 07:40:27 -0500 http://drugwonks.com/blog/a-virtual-ounce-of-prevention ICER’s policy prescriptions will cripple MS patients http://drugwonks.com/blog/icer-s-policy-prescriptions-will-cripple-ms-patients Thu, 16 Feb 2017 21:03:37 -0500 http://drugwonks.com/blog/icer-s-policy-prescriptions-will-cripple-ms-patients Vaccine Denial: The Original Alt Fact http://drugwonks.com/blog/vaccine-denial-the-original-alt-fact President Trump will ask prominent vaccine safety skeptic Robert F. Kennedy Jr. to lead a planned commission to study vaccine safety, Kennedy said Wednesday. Commission members will include "household names" who "have not taken a position on the issue" of vaccine safety, he said. Hm. Thu, 16 Feb 2017 08:14:01 -0500 http://drugwonks.com/blog/vaccine-denial-the-original-alt-fact Psst -- Wanna see some DNA? http://drugwonks.com/blog/psst-wanna-see-some-dna Thu, 16 Feb 2017 07:54:44 -0500 http://drugwonks.com/blog/psst-wanna-see-some-dna Panicking PBMs http://drugwonks.com/blog/panicking-pbms No wonder PBMs are running scared. When their profits and practices are made transparent they should be afraid – very afraid. Wed, 15 Feb 2017 07:46:13 -0500 http://drugwonks.com/blog/panicking-pbms Marathon Pharma Has a Golden Opportunity to Lead a Revolution on Drug Pricing http://drugwonks.com/blog/marathon-pharma-has-a-golden-opportunity-to-lead-a-revolution-on-drug-pricing Tue, 14 Feb 2017 08:09:30 -0500 http://drugwonks.com/blog/marathon-pharma-has-a-golden-opportunity-to-lead-a-revolution-on-drug-pricing PBM Lobby Memo Tells Trump: Give Us More Power To Pocket Rebates http://drugwonks.com/blog/pbm-lobby-memo-tells-trump-give-us-more-power-to-pocket-rebates PBMs asks Trump to let them hurt more patients Thu, 09 Feb 2017 14:54:27 -0500 http://drugwonks.com/blog/pbm-lobby-memo-tells-trump-give-us-more-power-to-pocket-rebates Reduce Drug Prices by Cutting Out PBM Rebates http://drugwonks.com/blog/reduce-drug-prices-by-cutting-out-pbm-rebates Wed, 08 Feb 2017 12:25:33 -0500 http://drugwonks.com/blog/reduce-drug-prices-by-cutting-out-pbm-rebates Trump Misunderstands Drug Pricing http://drugwonks.com/blog/trump-misunderstands-drug-pricing President Trump recently pledged to let federal officials negotiate the prices of drugs covered under Medicare. He claims this will save taxpayers billions of dollars. Nobody doubts that Trump and his team are shrewd negotiators. But the sorts of "negotiations" that Trump refers to have nothing in common with haggling over a real estate deal. Instead, the action that Trump has proposed — repealing the non-interference clause, originally drafted by Democratic Senators Ted Kennedy and Tom Daschle — would result in Medicare drug prices going up and patient choice going down. Thu, 02 Feb 2017 08:44:47 -0500 http://drugwonks.com/blog/trump-misunderstands-drug-pricing ICER's New Value Framework Still Discriminates Against the Sick http://drugwonks.com/blog/icer-s-new-value-framework-still-discriminates-against-the-sick Wed, 01 Feb 2017 18:06:44 -0500 http://drugwonks.com/blog/icer-s-new-value-framework-still-discriminates-against-the-sick Virginia partners with Purdue on PMPs http://drugwonks.com/blog/virginia-partners-with-purdue-on-pmps Governor Terry McAuliffe today announced that the Prescription Monitoring Program has been awarded a grant to help integrate use of its data in doctors’ and pharmacists’ regular work flow. The $3 million grant from PurduePharma will allow the Department of Health Professions to connect the state PMP with electronic health records (EHR ) used by Virginia doctors and pharmacies. Thu, 26 Jan 2017 09:57:50 -0500 http://drugwonks.com/blog/virginia-partners-with-purdue-on-pmps FDA and Off-Label: A Very Betamax Approach http://drugwonks.com/blog/fda-and-off-label-a-very-betamax-approach “I wonder if this memo was written on an electric typewriter -- since it seems to represent thinking from the 1980s,” Pitts wrote to Inside Health Policy. Mon, 23 Jan 2017 11:50:01 -0500 http://drugwonks.com/blog/fda-and-off-label-a-very-betamax-approach Bad Ad Program a Waste of FDA Time and Resources http://drugwonks.com/blog/bad-ad-program-a-waste-of-fda-time-and-resources Pitts called the original bad ad program "a complete waste of time," maintaining that FDA never really determined what was a bad ad, and that FDA should instead be focusing on regulating safety and efficacy. "FDA does not regulate creativity," Pitts added. Mon, 23 Jan 2017 11:42:12 -0500 http://drugwonks.com/blog/bad-ad-program-a-waste-of-fda-time-and-resources An Off-Label Regualtory Temper Tantrum http://drugwonks.com/blog/an-off-label-regualtory-temper-tantrum “This memo is a regulatory temper tantrum,” said Peter Pitts, a former FDA associate commissioner who heads the Center for Medicine in the Public Interest, a think tank that is funded, in part, by industry. “The memo is written to show that allowing the sharing of truthful, accurate, and non-misleading of information will cause the earth to stop spinning on its axis, research into new indications to cease, and misleading and misbranded communications to proliferate.” Mon, 23 Jan 2017 09:53:42 -0500 http://drugwonks.com/blog/an-off-label-regualtory-temper-tantrum JAMA Publishes Fake Science Study of Industry Influence of Patient Groups http://drugwonks.com/blog/jama-publishes-fake-science-study-of-industry-influence-of-patient-groups Closer to libel than truth Fri, 20 Jan 2017 08:11:47 -0500 http://drugwonks.com/blog/jama-publishes-fake-science-study-of-industry-influence-of-patient-groups Off Label back on the table http://drugwonks.com/blog/off-label-back-on-the-table FDA has released two new documents that address off-label communications about medical products. A draft guidance outlined questions and answers regarding communication with payers about healthcare economic information, including information concerning unapproved uses of medical products. A separate memorandum described the agency's position on sharing information about off-label use of approved drugs. Thu, 19 Jan 2017 00:56:58 -0500 http://drugwonks.com/blog/off-label-back-on-the-table FDA marches towards interchangeability http://drugwonks.com/blog/fda-marches-towards-interchangeability The FDA’s new draft guidance on interchangeability of biosimilars will require most biosimilars' sponsors to conduct studies showing that switching between a biosimilar and its reference product poses no greater risk than continuing to use the reference product. The guidance recommended designs for switching studies, as well as integrated trials to show that a compound is both biosimilar to and interchangeable with its reference biologic. Tue, 17 Jan 2017 23:45:42 -0500 http://drugwonks.com/blog/fda-marches-towards-interchangeability